Health Editor’s Note: You might have received a diagnosis of cancer and have had all the treatments/surgery to remove it from your body. You might have been deemed to be “free” of cancer, only to find out that the cancer is back, either in its original location or somewhere else in your body.
When cancer has moved to another place in your body, it has metastasized. Metastasis means the cancer is essentially out of control and will be harder to remove. When the doctor uses the M word, your prognosis seems to have taken a turn for the worse.
Now we see that there is a distinct possibility/probability that the “escaped and now living somewhere else in your body cancer cells” can be successfully subdued. Potentially, metarrestin, could be used as a treatment for cancer, after surgical tumor removal, instead of chemotherapy. Since this drug kills only the cancer cell, there should be less side effects than with typical chemotherapies, which kill “any” rapidly dividing cell. Most of the cells in our bodies are subject to attack by chemotherapy, thus hair loss, vomiting, diarrhea, etc. If the drug targets only the cancer cells, there should be less side effects realized. There are anti-cancer drugs now that target only specific cancer cells and this will be another bullet in the anti-cancer cell arsenal.
This drug is currently being developed to treat metastasis of cancer cells and seems to work on pancreatic and prostate cancers. If you or a friend or loved one is in the unfortunate current position of being diagnosed as having cancer metastasis, take this word, metarrestin, to your oncologist and see if there are trials for this drug that you can join. Even if you have not been diagnosed with prostate or pancreatic cancer, you have to explore every path….Carol
NIH, Northwestern scientists develop potential new approach to stop cancer metastasis
A compound breaks down a component of cancer cells.
The compound metarrestin breaks down a component of cancer cells called the perinucleolar compartment (PNC). PNCs are found only in cancer cells, and in a greater number of cells in advanced cancer. In the four panels on the left, the green dots indicate the presence of PNCs in untreated pancreatic and metastatic liver tumors. On the right, treatment with metarrestin reduced the prevalence of PNCsFrankowski et al., Sci. Transl. Med. 10, eaap8307 (2018)
Researchers have identified a compound that blocks the spread of pancreatic and other cancers in various animal models. When cancer spreads from one part of the body to another in a process called metastasis, it can eventually grow beyond the reach of effective therapies. Now, there is a new plan of attack against this deadly process, thanks to scientists at the National Institutes of Health, Northwestern University and their collaborative research partners.
The team collaborated to identify a compound, which they named metarrestin, that stopped tumor metastasis in multiple animal models. Mice treated with metarrestin also had fewer tumors and lived longer than mice that did not receive treatment. These results were published May 16, 2018 in Science Translational Medicine (link is external).
“Many drugs are aimed at stopping cancer growth and killing cancer cells,” said co-author Juan Marugan, Ph.D., group leader of the NIH’s National Center for Advancing Translational Sciences (NCATS) Chemical Genomics Center. “However, there is no single approved drug specifically aimed at treating metastasis. Our results show metarrestin is a very promising agent that we should continue to investigate against metastasis.”
In patients, metarrestin potentially could be effective as a therapy after cancer surgery. Because advanced cancers are difficult to completely remove with surgery, doctors typically give chemotherapy to try to kill undetected cancer cells left behind and prevent the cancer from coming back. Metarrestin could be added to such standard drug therapy.
Metarrestin breaks down an incompletely understood component of cancer cells called the perinucleolar compartment (PNC). PNCs are found only in cancer cells, and in a higher number of cells in advanced cancer, when it has spread to other sites in the body.
Co-author Sui Huang, M.D., Ph.D., and her colleagues at Northwestern University Feinberg School of Medicine, Chicago, showed early on that the more cancer cells with PNCs in a tumor, the more likely it would spread. Her findings suggested that reducing PNCs might translate to less cancer progression and possibly better outcomes in patients.
A compound breaks down a component of cancer cells.
The compound metarrestin halts the spread of cancer in animal models. In this image, the liver of an untreated mouse (top) shows metastatic tumors (arrows). After treatment with metarrestin, the tumors are greatly reduced (bottom). Frankowski et al., Sci. Transl. Med. 10, eaap8307 (2018)
To test these ideas, Huang approached Marugan to tap into NCATS’ expertise in screening, chemistry, compound development and testing to evaluate more than 140,000 compounds for their potential effectiveness in eliminating PNCs in cells in advanced cancer.
While nearly 100 compounds initially showed some activity, the investigators identified one compound that could effectively break down PNCs in advanced prostate cancer cells. With the help of researchers at the University of Kansas, Lawrence, they modified the compound to make it work better as a potential drug and evaluated the effects of the molecule in different assays, or tests, in the laboratory. They found that metarrestin could block the way prostate and pancreatic cancer cells spread.
In collaboration with co-author Udo Rudloff, M.D., Ph.D., from NIH’s National Cancer Institute’s (NCI) Center for Cancer Research, the group evaluated the effects — including toxicity — of metarrestin in pancreatic cancer mouse models. The investigators found that it prevented the further spread of pancreatic cancer by disrupting the protein-making machinery of cancer cells, and mice treated with metarrestin lived longer than mice without treatment.
“Cancer cells are rapidly dividing and need to make more proteins than healthy cells to help carry out various activities, including the ability to spread,” Rudloff said. “Interfering with the system stalls cancer cell metastasis.”
Rudloff and his NCI group currently are working with scientists at the NCATS-led Bridging Interventional Development Gaps program to collect the pre-clinical data on metarrestin needed to further its development as a candidate drug. The scientists plan to file an Investigational New Drug (IND) application in the fall with the U.S. Food and Drug Administration (FDA). FDA IND approval is necessary before a candidate drug can be tested in patients.
The research was funded by NCATS and NCI through their intramural programs, and in addition, the National Human Genome Research Institute grant U54HG005031, the National Institute of General Medical Sciences grants R01GM078555 and R01GM115710, NCI grant 2 P30 CA060553-19, the V Foundation, a donation from the Baskes family to the Robert H. Lurie Comprehensive Cancer Center, donations from ‘Running for Rachel’ and the Pomerenk family via the Rachel Guss and Bob Pomerenk Pancreas Cancer Research Fellowship to NCI, the Robert H. Lurie Comprehensive Cancer Center – Translational Bridge Program Fellowship in Lymphoma Research and the Molecular Libraries Initiative funding to the University of Kansas Specialized Chemistry Center.
About the National Center for Advancing Translational Sciences (NCATS): NCATS conducts and supports research on the science and operation of translation — the process by which interventions to improve health are developed and implemented — to allow more treatments to get to more patients more quickly. For more information about how NCATS is improving health through smarter science, visit https://ncats.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
Carol graduated from Riverside White Cross School of Nursing in Columbus, Ohio and received her diploma as a registered nurse. She attended Bowling Green State University where she received a Bachelor of Arts Degree in History and Literature. She attended the University of Toledo, College of Nursing, and received a Master’s of Nursing Science Degree as an Educator.
She has traveled extensively, is a photographer, and writes on medical issues. Carol has three children RJ, Katherine, and Stephen – one daughter-in-law; Katie – two granddaughters; Isabella Marianna and Zoe Olivia – and one grandson, Alexander Paul. She also shares her life with her husband Gordon Duff, many cats, and two rescues.